Acute Leukemia – Relapsed/Refractory

Studies Coming Soon for no specific mutation/target:
- IRB# 15588 (SMMART Trial)
- IRB# TBD
- Study Coming Soon EAY131 MATCH

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda.so/knight.php

Wild-Type TP1
IRB# 19008: A Phase ½ Galinpepimut-S in combination with Pembrolizumab

No specific mutation/ target
- IRB# 17577: Phase 1, AZD5991
- IRB# 18238: Phase 1, Ruxolitinib + Venetoclax

Genetic mutation/ target
- IRB# 19290: Phase 1b, PLX2853
- IRB# 19339: Phase III, CHAM vs. HAM

Post-transplant
- IRB# 17583: Phase 2 study of CSF1R inhibitor JNJ-40346527

IRB# 7195: Phase 2 Kinase Inhibition, individualized targeted therapies
IRB# 17379: Phase 1b, study of PDR001 and/or MBG453 in combination with decitabine
IRB# 17583: Phase 2 study of CSF1R inhibitor JNJ-40346527
IRB# 18253: Phase 1, Voruciclib

IRB# 17583: Phase 2 study of CSF1R inhibitor JNJ-40346527

EAY131 MATCH
IRB# 18253: Phase 1, Voruciclib

Cross-Disease Study for Relapsed and Refractory:
- IRB# TBD
- Study Coming Soon EAY131 MATCH